WHITEHOUSE STATION, N.J. & BOSTON--(BUSINESS WIRE)--March 9, 2006--Merck & Co., Inc. and Paratek Pharmaceuticals, Inc. announced today that Paratek has entered into an exclusive, worldwide collaborative development and license agreement with Merck --through an affiliate -- for PTK 0796, a novel, broad-spectrum aminomethylcycline (AMC) antibiotic with oral and intravenous (IV) formulations currently in Phase I clinical testing.
